Clinical Trials

Ovarian Neoplasms

NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

29 enrolled

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05891171 2026-06-05

ARC-25

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

40 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT06257264 2026-06-05

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BreastGastrointestinalGenitourinaryGynecologicThoracic

103 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06710756 2026-06-05

Lead-212 PSV359 Therapy for Patients With Solid Tumors

GastrointestinalGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

112 enrolled

Esophageal Neoplasms, Head and Neck Neoplasms, Mesothelioma, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT06885697 2026-06-05

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Phase 1 Recruiting

100 enrolled

GastrointestinalGynecologicOther solid neoplasmThoracic

Colonic Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thymoma, Thymus Neoplasms

NCT07282158 2026-06-05

Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians

Phase NA Recruiting

25 enrolled

GastrointestinalGynecologic

Mental Disorders, Ovarian Neoplasms

NCT01719926 2026-06-04

PIFA

Phase 1 Completed

13 enrolled

Esophageal Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT03132922 2026-06-04

MAGE-A4ᶜ¹º³²T for Multi-Tumor

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

71 enrolled 20 charts

Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT04300556 2026-06-04

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

BreastGynecologicThoracic

182 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04729387 2026-06-04

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3 Terminated

358 enrolled 19 charts

Ovarian Neoplasms

NCT04895709 2026-06-04

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

1,109 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05768139 2026-06-04

PIKALO-1

BreastGynecologicHead & Neck

880 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT05887609 2026-06-04

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

53 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05949632 2026-06-04

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

Phase 1/2 Terminated

5 enrolled 13 charts

GynecologicSarcoma

Adenocarcinoma, Mucinous, Carcinosarcoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Cystadenocarcinoma, Serous

NCT06760819 2026-06-04

panSOHO

BreastGastrointestinalGenitourinaryGynecologicSarcoma

111 enrolled

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors

NCT07059845 2026-06-04

FLORENZA

400 enrolled

GastrointestinalGynecologic

Ovarian Neoplasms

NCT07098182 2026-06-04

Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique)

Phase NA Recruiting

50 enrolled

Colonic Neoplasms, Ovarian Neoplasms, Rectal Neoplasms

NCT07213791 2026-06-04

FiREBOLT

Phase 1 Recruiting

241 enrolled

BreastGastrointestinalGynecologic

Pancreatic Intraductal Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT07625137 2026-06-04

Preventing Ovarian Cancer Through Opportunistic Salpingectomy at the Time of Laparoscopic Cholecystectomy

Phase NA Not yet recruiting

240 enrolled

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT02446600 2026-06-03

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT05523440 2026-06-03

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

Phase 2 Terminated

9 enrolled 10 charts

Ovarian Neoplasms, Endometrial Neoplasms

NCT05554328 2026-06-03

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

165 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05579366 2026-06-03

RAINFOL-01

BreastGynecologicOther solid neoplasmThoracic

884 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05797168 2026-06-03

FONTANA

506 enrolled

GynecologicThoracic

Adenocarcinoma of Lung, Ovarian Neoplasms, Endometrial Neoplasms

NCT06412120 2026-06-03

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

Phase 4 Recruiting

70 enrolled

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT06433219 2026-06-03

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

63 enrolled

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

NCT07038369 2026-06-03

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

BreastGenitourinaryGynecologic

134 enrolled

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07489287 2026-06-03

GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer

Phase 1 Not yet recruiting

18 enrolled

Phase 3 Not yet recruiting

Ovarian Neoplasms

NCT07564141 2026-06-03

RAINFOL™-07

688 enrolled

Phase 1 Not yet recruiting

Ovarian Neoplasms

NCT07623369 2026-06-03

A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors

56 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04454450 2026-06-02

Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer

Phase NA Active not recruiting

10 enrolled

GynecologicHead & NeckThoracic

Ovarian Neoplasms

NCT04881045 2026-06-02

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

Phase 1 Completed

29 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT05056077 2026-06-02

TTBF

Phase NA Active not recruiting

353 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Kidney Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Endometrial Neoplasms

NCT05417594 2026-06-02

CERTIS1

BreastCNSGastrointestinalGenitourinaryGynecologic

695 enrolled

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT05445778 2026-06-02

GLORIOSA

Phase 3 Active not recruiting

520 enrolled

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

2,900 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05739981 2026-06-02

MRD

30 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05787587 2026-06-02

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

216 enrolled

Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related, Breast Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06619236 2026-06-02

RAINFOL-02

Phase 3 Active not recruiting

448 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06915025 2026-06-02

OVATION-3

Phase 3 Recruiting

500 enrolled

Phase NA Active not recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07120945 2026-06-02

Embrace Gyn

70 enrolled

GynecologicOther neoplasm

Uterine Cervical Neoplasms, Endometriosis, Leiomyoma, Menstruation Disturbances, Ovarian Neoplasms, Precancerous Conditions, Uterine Prolapse, Endometrial Neoplasms, Adenomyosis

NCT07225270 2026-06-02

RAINFOL-04

Phase 3 Recruiting

528 enrolled

Phase 3 Not yet recruiting

Ovarian Neoplasms

NCT07604766 2026-06-02

RAINFOL-02

82 enrolled

Phase 2/3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02839707 2026-06-01

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

444 enrolled 17 charts

DermatologicGynecologicHead & NeckSarcoma

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05039801 2026-06-01

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Phase 1 Recruiting

54 enrolled

Squamous Cell Carcinoma of Head and Neck, Chondrosarcoma, Melanoma, Ovarian Neoplasms, Endometrial Neoplasms

NCT05231122 2026-06-01

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

80 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05364879 2026-06-01

Prehabilitation for Ovarian Cancer Patients

Phase NA Recruiting

108 enrolled